ArticleCureus2026
Efficacy of Biologics in the Management of Pediatric Asthma: A Single-Center Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Biologics are monoclonal antibodies that target immune mediators of allergic asthma. Their use in children is not as well studied as in adults, and many indications are extrapolated from data conducted with adults. This study aims to evaluate the efficacy of biologics in improving respiratory function and reducing asthma-related morbidities in children and adolescents in a single health system, to compare efficacy between different biologics, and to explore whether differences in baseline biomarkers correlate with differing outcomes. Methods With IRB approval, a retrospective chart review study was conducted on patients with a diagnosis of asthma initiated on a biologic between 2019 and 2023. Indicators of morbidity (asthma severity, number of steroid courses, emergency room visits, hospitalizations), pulmonary function, and biomarker levels (IgE, eosinophils) were assessed for a year before and after biologic initiation. Outcomes pre- and post-biologic initiation were compared using dependent sample t-testing, conducted using IBM SPSS Statistics for Windows, Version 29 (Released 2023; IBM Corp., Armonk, New York, United States). Results One hundred and seventy-six subjects were included in our study. Biologics overall reduced morbidity and improved pulmonary function in children. Morbidity was decreased specifically with omalizumab and dupilumab, while pulmonary function also improved with dupilumab. Mepolizumab, benralizumab, and tezepelumab had small sample sizes, which limited the power of results from their groups. No significant differences in outcomes were noted between groups with different baseline biomarker levels. Conclusions We find that initiation of biologics in children and adolescents with poorly controlled asthma is associated with improvements in terms of morbidity and pulmonary function. Further data is needed on agents less commonly prescribed and for individual agents based on biomarker levels to better understand what role these agents have in managing pediatric asthma and help guide their continued use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.